Matching articles for "letrozole"
Issue 1717 · December 9, 2024
Ribociclib (Kisqali) for Early Breast Cancer (online only)

The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis), which was approved by the FDA in 2017 for use with an aromatase inhibitor or fulvestrant for treatment of hormone…

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):e202-3 doi:10.58347/tml.2024.1717f
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis), which was approved by the FDA in 2017 for use with an aromatase inhibitor or fulvestrant for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, has now been approved for use with an aromatase inhibitor for adjuvant treatment of HR-positive, HER2-negative stage II or III early breast cancer at high risk of recurrence. Kisqali can be used in patients with node-positive or node-negative disease. The CDK 4/6 inhibitor abemaciclib (Verzenio) is also approved for use in early breast cancer, but only in patients with node-positive disease.
Issue 1679 · June 26, 2023 Free
In Brief: Alternatives to Mifepristone for Medication Abortion

The possibility that use of mifepristone ( Mifeprex , and generics) may be restricted has led to questions about alternatives for medication abortion.

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):102-3 doi:10.58347/tml.2023.1679d
The possibility that use of mifepristone ( Mifeprex , and generics) may be restricted has led to questions about alternatives for medication abortion.
Issue 1671 · March 6, 2023
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer

The FDA has approved elacestrant ( Orserdu – Stemline), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative,…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):38-40 doi:10.58347/tml.2023.1671d
The FDA has approved elacestrant ( Orserdu – Stemline), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in postmenopausal women or men who had disease progression following endocrine therapy. Elacestrant is the first oral selective estrogen receptor degrader (SERD) to be approved for treatment of breast cancer; the injectable SERD fulvestrant ( Faslodex , and generics) was approved more than 20 years ago.
Issue 1533 · November 6, 2017
Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer

The FDA has approved abemaciclib ( Verzenio – Lilly), an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2017 Nov 6; 59(1533):185-6
The FDA has approved abemaciclib ( Verzenio – Lilly), an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Abemaciclib is the third CDK 4/6 inhibitor to be approved in the US for this indication.
Issue 1532 · October 23, 2017
Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (online only)

The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line endocrine-based therapy in…

Med Lett Drugs Ther. 2017 Oct 23; 59(1532):e178-9
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib ( Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line endocrine-based therapy in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib is also available copackaged with the aromatase inhibitor letrozole ( Femara , and generics) as Kisqali Femara Co-Pack . Ribociclib is the second CDK 4/6 inhibitor to be approved in the US for this indication; palbociclib (Ibrance) was the first. Abemaciclib (Verzenio) , a third CDK 4/6 inhibitor, was recently approved and will be reviewed in a future issue.
Issue 1475 · August 17, 2015
Palbociclib (Ibrance) for Metastatic Breast Cancer

Palbociclib ( Ibrance – Pfizer), an oral cyclin-dependent kinase inhibitor, has been approved by the FDA for use in combination with the aromatase inhibitor letrozole ( Femara , and generics) for first-line…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):115-6
Palbociclib ( Ibrance – Pfizer), an oral cyclin-dependent kinase inhibitor, has been approved by the FDA for use in combination with the aromatase inhibitor letrozole ( Femara , and generics) for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. It is the first cyclin-dependent kinase inhibitor to become available in the US.
Issue 1376 · October 31, 2011
Drugs for Ovulation Induction

Infertility occurs in about 15% of couples. About one-third of cases are due to problems with ovulation or other female factors, another third are due to a male infertility factor, and the remaining third are…

Med Lett Drugs Ther. 2011 Oct 31; 53(1376):86-8
Infertility occurs in about 15% of couples. About one-third of cases are due to problems with ovulation or other female factors, another third are due to a male infertility factor, and the remaining third are unexplained. In older women, unexplained infertility is probably caused by diminished quality and quantity of oocytes. The first approach to treatment of female-factor infertility generally is the use of drugs that stimulate oocyte production.
Issue 1366 · June 13, 2011
Aromatase Inhibitors for Adjuvant Treatment of Postmenopausal Breast Cancer

Adjuvant hormone therapy with anti-estrogen drugs has been shown to reduce disease recurrence and mortality in postmenopausal women with estrogen receptor (ER)-positive breast cancer. In recent years,…

Med Lett Drugs Ther. 2011 Jun 13; 53(1366):47-8
Adjuvant hormone therapy with anti-estrogen drugs has been shown to reduce disease recurrence and mortality in postmenopausal women with estrogen receptor (ER)-positive breast cancer. In recent years, aromatase inhibitors (AI) have become the preferred first-line hormonal treatment over tamoxifen for such patients.1,2
Issue 29 · January 1, 2005
Drugs for Breast Cancer

In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for…

Treat Guidel Med Lett. 2005 Jan; 3(29):1-6
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Issue 1135 · July 22, 2002
Fulvestrant (Faslodex) for Advanced Breast Cancer

Fulvestrant ( Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast…

Med Lett Drugs Ther. 2002 Jul 22; 44(1135):65-6
Fulvestrant ( Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast cancer in postmenopausal women with disease progession on tamoxifen ( Nolvadex , and others) or another antiestrogen.
Issue 1087 · September 18, 2000
Drugs of Choice For Cancer Chemotherapy (combined issue 1087-1088)

The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for…

Med Lett Drugs Ther. 2000 Sep 18; 42(1087):83-92
The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For many of the cancers listed, surgery and/or radiation therapy are also part of the management of the disease.
Issue 1076 · April 17, 2000
Exemestane For Advanced Breast Cancer

The FDA has approved exemestane, an aromatase inhibitor, for the treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen.

Med Lett Drugs Ther. 2000 Apr 17; 42(1076):35-6
The FDA has approved exemestane, an aromatase inhibitor, for the treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen.